Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
基本信息
- 批准号:7257306
- 负责人:
- 金额:$ 30.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-08 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:4q21ArteriesAspartateBone MatrixC-terminalCathepsins BCell membraneChromosomesCleaved cellDataDefectDiseaseEnd PointEndopeptidasesFamilial hypophosphatemic bone diseaseFractureFunctional disorderHealthIn VitroInheritedKidneyKidney CalculiMapsMetabolismMetalloendopeptidasesMetalloproteasesMineralsMiningModelingMolecularNatureNumbersOdontoblastsOsteoblastsOsteogenesisOsteomalaciaOsteoporosisPHEX proteinPeptide HydrolasesPeptidesPeriodontal DiseasesPhysiologic calcificationPlayProteinsRattusRenal OsteodystrophyResearchResearch PersonnelResistanceRicketsRiskRoleSalivary ProteinsSerineSerumSkeletonTooth structureVitamin Dbonecalcificationin vivoinhibitor/antagonistinorganic phosphatemineralizationosteopontinprogramsprotein protein interactionrenal arterystatherintumor
项目摘要
DESCRIPTION (provided by applicant):
Inherited and tumor acquired bone-mineral disorders have provided powerful models that have helped understand some of the molecular-mechanisms responsible for maintaining a healthy, dynamic, mineralized-skeleton. X-linked hypophosphatemic rickets (HYP) is one such disease and is associated with severe defects in mineralization, renal phosphate handling, and vitamin D metabolism. MEPE, (a bone-matrix protein) and osteoblastic-proteases are elevated markedly in HYP. Also, PHEX, an osteoblast-expressed, plasma-membrane anchored Zn-metallopeptidase is the primary defect responsible for the disease. We have substantive preliminary data that supports the hypothesis that a protein-protein interaction between MEPE and PHEX regulates mineralization. PHEX protects MEPE from proteolytic cleavage by proteases (notably cathepsin B) in-vitro and osteoblastic-proteases are elevated in Hyp. In the absence of PHEX, MEPE is cleaved, releasing a phosphorylated, acidic, serine-aspartate rich, C-terminal fragment (ASARM-peptide). The ASARM-peptide (2 kDa), is remarkably resistant to a vast array of proteases resulting in increased levels in Hyp. The ASARM-peptide inhibits mineralization and elevated ASARM-peptide is proposed to be wholly or in part responsible for the mineralization defects. This application will focus on the role of MEPE and ASARM-peptides in mineralization. Our specific aims are: 1. Structural characterization and quantification of MEPE ASARM-peptide(s) in-vitro and in-vivo in normal and Hyp osteoblasts and serum. 2. Determination of MEPE ASARM-peptide effects on mineralization in-vitro and in-vivo. 3. Elucidation of MEPE-PHEX protein-protein interactions. 4. The role of elevated protease(s) in Hyp-osteoblasts in relation to abnormal mineralization and MEPE-PHEX interactions. The ASARM-motif is present in a number of tooth-bone matrix and salivary proteins. These include MEPE, DMP1, osteopontin, statherin, DSPP that all map to chromosome 4q21. Thus, the elucidation of its role in mineralization is of prime importance for understanding bone mineralization mechanisms. Importantly, the part the motif plays will have relevance to the treatment and understanding of bone-fracture risk, osteoporosis, tumor-induced osteomalacia (OHO), HYP, periodontal disease, disorders of mineralization in teeth, bone, renal-stones and ectopic calcifications in arteries and renal-osteodystrophy.
描述(由申请人提供):
遗传性和肿瘤获得性骨矿物质疾病提供了强大的模型,有助于理解负责维持健康,动态,矿化骨骼的一些分子机制。X连锁低磷血症性佝偻病(HYP)就是这样一种疾病,与矿化、肾磷酸盐处理和维生素D代谢的严重缺陷有关。MEPE(一种骨基质蛋白)和成骨细胞蛋白酶在HYP中显著升高。此外,PHEX,成骨细胞表达,质膜锚定锌金属肽酶是主要的缺陷负责的疾病。我们有实质性的初步数据支持的假设,MEPE和PHEX之间的蛋白质-蛋白质相互作用调节矿化。PHEX在体外保护MEPE免受蛋白酶(特别是组织蛋白酶B)的蛋白水解切割,并且Hyp中成骨蛋白酶升高。在不存在PHEX的情况下,MEPE被切割,释放出磷酸化的、酸性的、富含丝氨酸-天冬氨酸的C-末端片段(ASARM-肽)。ASARM-肽(2kDa)对大量蛋白酶具有显著抗性,导致Hyp水平增加。ASARM-肽抑制矿化,并且提出升高的ASARM-肽是矿化缺陷的全部或部分原因。本申请将重点关注MEPE和ASARM-肽在矿化中的作用。我们的具体目标是:1. MEPE ASAM-肽在正常和Hyp成骨细胞和血清中的体外和体内结构表征和定量。2. MEPE ASARM-肽对体外和体内矿化作用的测定。3. MEPE-PHEX蛋白质-蛋白质相互作用的阐明。4. Hyp-osteoblast中升高的蛋白酶在异常矿化和MEPE-PHEX相互作用中的作用。ASARM基序存在于许多牙-骨基质和唾液蛋白中。这些包括MEPE、DMP 1、骨桥蛋白、statherin、DSPP,它们都定位于染色体4 q21。因此,阐明其在矿化中的作用对于理解骨矿化机制至关重要。重要的是,该基序所起的作用将与骨折风险、骨质疏松症、肿瘤诱导的骨软化(OHO)、HYP、牙周病、牙齿矿化障碍、骨、肾结石和动脉异位钙化以及肾骨营养不良的治疗和理解相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER S ROWE其他文献
PETER S ROWE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER S ROWE', 18)}}的其他基金
The Molecular Pathology and Etiology of Nephrogenic Systemic Fibrosis
肾源性系统纤维化的分子病理学和病因学
- 批准号:
9384115 - 财政年份:2017
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
6830580 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
8289459 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
7736587 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
7146933 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization and the Role of Matrixphosphoglycoprotein
基质磷酸糖蛋白的矿化和作用
- 批准号:
7150740 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization and the Role of Matrixphosphoglycoprotein
基质磷酸糖蛋白的矿化和作用
- 批准号:
6789566 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
8097964 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
6947829 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
Mineralization of the matrix in disease and health
疾病和健康中基质的矿化
- 批准号:
7088784 - 财政年份:2004
- 资助金额:
$ 30.75万 - 项目类别:
相似海外基金
Analysis of spatiotemporal involvement of retinoic acid in pharyngeal arch arteries
视黄酸对咽弓动脉的时空影响分析
- 批准号:
22KJ2601 - 财政年份:2023
- 资助金额:
$ 30.75万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Molecular identification of the oxygen sensor(s) in the fetal ductus arteriosus and pulmonary artery: an integrated multiomic comparison of mitochondria in vital fetal arteries with opposing oxygen responses
胎儿动脉导管和肺动脉中氧传感器的分子识别:对胎儿重要动脉中具有相反氧反应的线粒体进行综合多组学比较
- 批准号:
462691 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Operating Grants
Understanding the regulatory control of complex blood flow in conduit arteries and veins
了解导管动脉和静脉中复杂血流的调节控制
- 批准号:
RGPIN-2021-02563 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Discovery Grants Program - Individual
Fetal cerebral arteries and prenatal alcohol exposure
胎儿脑动脉和产前酒精暴露
- 批准号:
10337722 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Fetal cerebral arteries and prenatal alcohol exposure
胎儿脑动脉和产前酒精暴露
- 批准号:
10590708 - 财政年份:2022
- 资助金额:
$ 30.75万 - 项目类别:
Pregnenolone constricts cerebral vascular arteries through the direct modulation of BK ion channels
孕烯醇酮通过直接调节 BK 离子通道收缩脑血管动脉
- 批准号:
10441131 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Understanding the regulatory control of complex blood flow in conduit arteries and veins
了解导管动脉和静脉中复杂血流的调节控制
- 批准号:
DGECR-2021-00028 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Discovery Launch Supplement
Association of brain temperature increase and cerebrospinal fluid dynamics in chronic brain ischemia due to main trunk occlusion of cerebral arteries
脑动脉主干闭塞所致慢性脑缺血脑温度升高与脑脊液动力学的关系
- 批准号:
21K09108 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studying guinea pig development to discover how natural collateral arteries form
研究豚鼠的发育以发现自然侧支动脉是如何形成的
- 批准号:
10195510 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别:
Studying guinea pig development to discover how natural collateral arteries form
研究豚鼠的发育以发现自然侧支动脉是如何形成的
- 批准号:
10405492 - 财政年份:2021
- 资助金额:
$ 30.75万 - 项目类别: